EyeWorld Weekly, September 15, 2023

➤ FDA issues eight warning letters ➤ Positive Phase 2 safety update for investigational treatment of retinal diseases ➤ First-in-human titratable glaucoma therapy system ➤ Companies partner to develop biological dry eye treatment ➤ Geographic atrophy drug development discontinued ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, September 15, 2023